A targeted gene panel illuminates pathogenesis in young people with unexplained kidney failure

Area of Science:

• Genetics
• Nephrology
• Genomic Medicine

Background:

• Young-onset kidney failure often lacks clear causes, with genetics playing a significant role.
• National Health Service England introduced a comprehensive genomic testing service for unexplained renal disease in young individuals.
• This review assesses the initial clinical implementation and outcomes of this novel genomic testing service.

Purpose of the Study:

• To evaluate the effectiveness of the 'Unexplained Young-Onset End-Stage Renal Disease' (R257) gene panel.
• To determine the yield of genetic diagnoses in young patients with unexplained kidney failure using this service.
• To identify predictors of genetic diagnoses in this patient cohort.

Main Methods:

• The R257 gene panel, analyzing 175 renal disease-associated genes via next-generation sequencing, was used for patients under 36.
• Data from 71 patients tested between October 2021 and February 2022 were retrospectively reviewed.
• Phenotypic data were extracted, and referring clinicians were contacted for further details.

Main Results:

• A genetic diagnosis was confirmed in 32% (23/71) of patients, with an additional 3% (2/71) showing genetically suggestive variants.
• Nephronophthisis (NPHP1 variants) and Alport syndrome (COL4A3/COL4A4 variants) were the most frequent diagnoses.
• Family history of renal disease (60%) and extra-renal manifestations (48%) were associated with positive genetic findings.

Conclusions:

• The R257 gene panel successfully identified genetic diagnoses in a significant proportion of young patients with unexplained kidney failure.
• This study underscores the vital role of accessible genomic testing in diagnosing pediatric and young adult renal diseases.
• The findings support the expanding utility of genomic approaches in managing inherited kidney disorders.